High Serum Fractalkine/CX3CL1 in Patients with Chronic Obstructive Pulmonary Disease: Relationship with Emphysema Severity and Frequent Exacerbation
- 66 Downloads
The purpose of this study was to investigate the relationship between serum fractalkine (CX3CL1/FKN) level and the multi-slice spiral computed tomography (MSCT) emphysema index in Chinese patients with chronic obstructive pulmonary disease (COPD).
We detected chemokine CX3CL1 in serum from 95 Chinese patients with COPD by using an enzyme-linked immunosorbent assay. According to the MSCT emphysema index, the selected cases were divided into an emphysema-dominant group (n = 25) and a non-emphysema-dominant group (n = 70).
There were significant differences in body mass index and lung function between the two groups. The serum level of CX3CL1 in the emphysema-dominant group was significantly higher than that in the non-emphysema-dominant group. Through multivariate logistic regression analysis, it was found that high serum CX3CL1 levels were independently associated with emphysema, with a relative risk of 2.617 (95% CI 1.018–6.121; P = 0.029). The percentage of frequent acute exacerbations during the first year of follow-up was significantly higher in the high-level serum CX3CL1 group (P = 0.039). After 3 years of follow-up, there was no significant difference in the CT emphysema index between the high and low serum CX3CL1 groups (P = 0.503).
Our results suggest that the serum level of CX3CL1 is related to the MSCT emphysema index. Chemokine CX3CL1 might be a useful predictor for identifying frequent exacerbation and emphysema severity in patients with COPD.
KeywordsCX3CL1 Emphysema Frequent exacerbation CT emphysema index Chronic obstructive pulmonary disease
Compliance with Ethical Standards
Conflict of interest
All authors declare no conflicts of interest.
- 1.Kunisaki K, Dransfield M, Anderson J, Brook R, Calverley P, Celli B, Crim C, Hartley B, Martinez F, Newby D, Pragman A, Vestbo J, Yates J, Niewoehner D (2018) Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med 198(1):51–57CrossRefGoogle Scholar
- 5.Vogelmeier C, Criner G, Martinez F, Anzueto A, Barnes P, Bourbeau J, Celli B, Chen R, Decramer M, Fabbri L, Frith P, Halpin D, López Varela M, Nishimura M, Roche N, Rodriguez-Roisin R, Sin D, Singh D, Stockley R, Vestbo J, Wedzicha J, Agustí A (2017) Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med 195(5):557–582CrossRefGoogle Scholar
- 6.Lee J, Kwok S, Jung S, Lee J, Lee J, Baek S, Kim E, Ju J, Park S, Kim H (2014) Role of fractalkine in the pathogenesis of primary Sjögren syndrome: increased serum levels of fractalkine, its expression in labial salivary glands, and the association with clinical manifestations. J Rheumatol 41(12):2425–2438CrossRefGoogle Scholar
- 13.Zhang J, Patel J (2010) Role of the CX3CL1–CX3CR1 axis in chronic inflammatory lung diseases. Int J Clin Exp Med 3(3):233–244Google Scholar
- 15.Yanagawa M, Hata A, Honda O, Kikuchi N, Miyata T, Uranishi A, Tsukagoshi S, Tomiyama N (2018) Subjective and objective comparisons of image quality between ultra-high-resolution CT and conventional area detector CT in phantoms and cadaveric human lungs. Eur Radiol 28(5):2159–2168CrossRefGoogle Scholar